bone marrow and lymphatic organs cancers of the blood hematological malignacy
Conditions
Interventions
Suitable patients will be treated with a combined infusion of donor DC*s and
DLI which are loaded with relevant mHags. Patients with minimal 1 relevant
mismatch in the Graft versus Tumor direction a
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1.Patient with a measurable persistent disease after preceding DLI given for persistent or relapsed malignancy after allo-SCT. Reinduction chemotherapy in case of rapidly progressive disease (e.g. in AML) is allowed. 2. Recipient and donor with at least one relevant mismatch in mHags HA-1, HA-2, ACC1, ACC2, PANE1, LRH-1, CD19L or HB-1 in the Graft versus Tumor (GvT) direction (recipient mHag positive, donor mHag negative). 3. Recipient and donor positive for the relevant HLA, presenting the mismatched mHag(s). 4. Expression of the mismatched mHag in the lineage from which the malignancy has arisen. 5. Age 18-70 years 6. Absence of acute GvHD > grade 1 or extensive chronic GvHD 7. No prior or concomitant treatment for 8 weeks with immunosuppressive drugs such as prednisone, cyclosporine A and MMF. 8. WHO performance 0-2 (see appendix 1) 9. Absence of severe cardiac hepatic, renal, or metabolic disease 10. Written informed consent
Exclusion criteria
Exclusion criteria: 1. WHO performance 3-4 2. Presence of severe cardiac hepatic, renal, metabolic disease 3. Rapidly progressive disease, despite reinduction therapy 4. Life expectancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoints are the evaluation of safety and efficacy, the occurance of GvHD and the induction of a positive response to the combined DLI and DC treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| The immune effects of the combined modality including the induction of specific mHag responses | — |
Countries
Netherlands
Outcome results
None listed